Drug Identification System

PillID

← Blog 🌙

Gabapentin: Uses, Side Effects, and Abuse Potential Explained

Gabapentin — sold under the brand name Neurontin and dozens of generic labels — is one of the most prescribed drugs in the United States. Originally approved for epilepsy in 1993, it has since become a go-to medication for an extraordinarily wide range of conditions, from nerve pain to anxiety to alcohol withdrawal. Its ubiquity masks a complicated safety profile that has become increasingly evident as prescribing has expanded and abuse patterns have emerged. This guide covers what gabapentin actually does, what it's used for, and the growing concerns around its misuse.

What Gabapentin Actually Does (Not What the Name Implies)

The name "gabapentin" suggests a relationship with GABA (gamma-aminobutyric acid), the brain's primary inhibitory neurotransmitter. This is misleading. Gabapentin does not bind to GABA receptors, does not increase GABA levels, and does not mimic GABA's direct actions in any meaningful way. The name is a historical artifact from early research.

What gabapentin actually does is bind to the alpha-2-delta subunit of voltage-gated calcium channels in neurons. By occupying this subunit, it reduces calcium influx at presynaptic terminals, which decreases the release of excitatory neurotransmitters — particularly glutamate, norepinephrine, and substance P. The result is reduced neuronal excitability in circuits involved in pain signaling and seizure propagation. This mechanism is genuinely useful for certain conditions but also produces the sedation and cognitive effects that characterize the drug.

FDA-Approved Uses

Gabapentin has two primary FDA-approved indications: adjunctive treatment of partial-onset seizures in adults and pediatric patients (aged 3 and older), and management of postherpetic neuralgia — the nerve pain that persists after a shingles outbreak. Gralise and Horizant are extended-release formulations approved specifically for postherpetic neuralgia and restless leg syndrome, respectively.

Massive Off-Label Use

The reality of gabapentin prescribing looks very different from its approved label. Studies suggest that the majority of gabapentin prescriptions in the U.S. are written for off-label indications. These include:

• Neuropathic pain of various types (diabetic neuropathy, chemotherapy-induced peripheral neuropathy, spinal cord injury pain)
• Fibromyalgia — though evidence quality is modest
• Anxiety disorders and generalized anxiety, particularly in patients who can't tolerate or don't respond to SSRIs
• Alcohol withdrawal — increasingly used as an alternative or adjunct to benzodiazepines
• Opioid and other substance withdrawal
• Restless leg syndrome (also FDA-approved for Horizant specifically)
• Bipolar disorder, insomnia, migraine prevention, and perioperative pain

This breadth of use reflects both genuine clinical utility and the pharmaceutical marketing of Neurontin, which is the subject of one of the largest off-label marketing settlements in U.S. history — Pfizer paid $430 million in 2004 to resolve charges related to promoting gabapentin for unapproved uses.

The Gabapentinoid Class

Gabapentin belongs to a small drug class called gabapentinoids, which also includes pregabalin (Lyrica). Pregabalin shares the same mechanism of action but binds to the alpha-2-delta subunit with higher affinity and exhibits more predictable, linear pharmacokinetics. Pregabalin reached Schedule V controlled substance status at the federal level in 2005 — a scheduling decision that gabapentin has not received federally, despite having similar abuse characteristics. Many researchers and clinicians view this discrepancy as inconsistent.

Side Effects

Common side effects of gabapentin include sedation and dizziness (particularly at the start of therapy), cognitive slowing or "brain fog," peripheral edema (swelling in the legs and feet), weight gain with long-term use, and ataxia (unsteady gait). These effects are dose-dependent and often improve as tolerance develops. In elderly patients, sedation and cognitive effects are especially pronounced and can increase fall risk.

Less commonly, gabapentin can cause respiratory depression — this risk is low when the drug is used alone, but increases substantially when combined with opioids, benzodiazepines, or other CNS depressants. The FDA added a safety communication about this combination risk in 2019.

The Abuse Problem

Gabapentin misuse has grown considerably alongside its prescribing volume. At high doses, some users experience a euphoria described as similar to opioids or cannabis — a dissociative calm with mood elevation. More concerning is gabapentin's interaction with opioids: it enhances and prolongs the subjective opioid high, making it attractive for co-use. Studies of opioid overdose decedents have found gabapentin present in a substantial proportion — in some regional studies, over 20% of opioid deaths involved gabapentin, and the combination dramatically increases respiratory depression risk compared to either drug alone.

State-Level Scheduling and Withdrawal

In response to rising misuse, several states have classified gabapentin as a Schedule V controlled substance, including Kentucky, Tennessee, Michigan, Virginia, and others. This imposes prescription monitoring requirements and limits on refills. Federal scheduling has been discussed but not implemented as of 2026. Gabapentin produces physical dependence with regular use, and abrupt discontinuation can cause a withdrawal syndrome including anxiety, insomnia, nausea, sweating, and — importantly — seizures. Tapering should always be supervised by a physician.

Frequently Asked Questions

What is gabapentin used for?

Gabapentin (brand name Neurontin) is FDA-approved for two conditions: epilepsy (as an adjunctive treatment for partial-onset seizures) and postherpetic neuralgia, the nerve pain that follows shingles. It is also widely prescribed off-label for a broad range of conditions including diabetic peripheral neuropathy, restless leg syndrome, anxiety disorders, alcohol withdrawal, and chronic pain states — uses for which evidence ranges from well-supported to modest.

Is gabapentin addictive or a controlled substance?

Gabapentin is not classified as a controlled substance at the federal level, but its abuse potential has been increasingly recognized. Several U.S. states — including Kentucky, Tennessee, Michigan, and others — have reclassified it as a Schedule V controlled substance at the state level. Gabapentin misuse is particularly associated with patients who also use opioids, as the combination amplifies opioid effects and significantly increases overdose risk. Dependence and withdrawal can occur with regular use.

Why is gabapentin dangerous when combined with opioids?

Gabapentin enhances opioid-induced respiratory depression in a supra-additive way — meaning the combined effect on breathing is greater than what either drug would produce alone. Epidemiological data has linked gabapentin co-prescription with a significantly elevated risk of opioid overdose death. The mechanism involves gabapentin's ability to suppress respiratory drive through its own CNS depressant effects on top of opioid-mediated respiratory depression.

What are the withdrawal symptoms from stopping gabapentin?

Stopping gabapentin abruptly after regular use can cause withdrawal symptoms including anxiety, insomnia, nausea, sweating, and — most seriously — seizures, even in patients who were taking gabapentin for non-epileptic conditions. The withdrawal syndrome can resemble benzodiazepine or alcohol withdrawal in severe cases. Gabapentin should always be tapered gradually under medical supervision rather than stopped suddenly, particularly after prolonged or high-dose use.